GLP-1 Hair Loss: Causes, Timeline & What To Do | PlexusDx

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

If you started a GLP-1 a few months ago and now you’re finding hair on your pillow, in the shower drain, and wrapped around your brush, you’re not imagining it — and you’re not alone. FDA labels confirm hair loss in roughly 3% of Wegovy users and 4–5% of Zepbound users in clinical trials, versus about 1% on placebo. The headline most people miss: in the overwhelming majority of cases, this is a side effect of rapid weight loss rather than a direct effect of the GLP-1 molecule itself. The condition has a name — telogen effluvium — it’s reversible, and the way you titrate, eat, and monitor over the first six months matters more than the brand on your pen. This guide walks the FDA evidence, the telogen effluvium timeline, why women report it more often, the genetic angle most providers skip, and where the PlexusDx Microdose GLP-1 Protocol, Semaglutide Injection, and Precision Peptide Genetic Test fit a hair-loss-aware treatment plan.

What the FDA labels actually say about GLP-1 hair loss

Hair loss appears in the FDA prescribing information for the two big weight-loss GLP-1s. Wegovy (semaglutide 2.4 mg) lists alopecia as a clinical-trial adverse reaction at roughly 3% in adults and 4% in adolescents, versus about 1% in adults on placebo. Zepbound (tirzepatide) lists hair loss as a common adverse reaction at 4–5% across doses versus approximately 1% on placebo, and notes it was reported more frequently in women. The diabetes-indication versions of the same molecules — Ozempic and Mounjaro — show alopecia in postmarketing reports rather than original trial data, almost certainly because their typical use produces less aggressive weight loss. Saxenda (liraglutide) added alopecia to its postmarketing section in a recent label revision. The signal is real, it’s dose- and weight-loss-related, and any responsible GLP-1 provider should discuss it before week one — not after the patient panics in month four.

It’s the weight loss, not the molecule (mostly)

The single most important data point comes from Canada’s Wegovy product monograph: patients who lost more than 20% of their body weight reported hair loss at 5.3%, versus 2.5% for those who lost less — roughly double the rate, tracking the magnitude of weight loss rather than dose of semaglutide. Bariatric surgery, very-low-calorie diets, postpartum recovery, and severe illness all trigger the same shedding pattern at much higher rates — bariatric patients experience telogen effluvium at rates reported up to 57% in the surgical literature. A 2025 University of British Columbia claims-data analysis flagged a 52% higher hair-loss risk on semaglutide compared to bupropion-naltrexone, but bupropion-naltrexone produces dramatically less weight loss, so the comparison reflects intensity of weight change as much as anything molecular. FDA Adverse Event Reporting System disproportionality signals exist for both semaglutide and tirzepatide — worth tracking, not proof the drug itself breaks follicles.

Telogen effluvium: the actual mechanism behind the shed

Telogen effluvium is a non-scarring, diffuse shedding pattern triggered when a stressor pushes a larger-than-normal share of hair follicles from the active growth phase (anagen) into the resting phase (telogen) all at once. About 2–3 months after the trigger, those resting follicles release their hairs together, producing the dramatic shedding you see in months 3–5. The classic GLP-1 triggers are the ones any rapid weight-loss program creates: a sudden caloric drop, protein intake falling below maintenance because appetite is suppressed, micronutrient gaps as portion sizes shrink, and the metabolic shift of significant fat loss. Telogen effluvium is reversible. Once the trigger stabilizes — meaning weight stops dropping rapidly, protein intake recovers, and any deficiencies are corrected — the follicles re-enter anagen and visible regrowth begins within 3–6 months, with full density typically restored within 9–12 months. The shedding is alarming. The biology is forgiving.

The GLP-1 hair-loss timeline you can actually plan around

Timing is consistent enough across patients that you can plan around it. Months 1–2: shedding usually hasn’t started yet because the telogen pipeline takes weeks to fill. Months 2–4: shedding begins and accelerates — this is when most patients first notice extra hair in the brush or drain. Months 4–6: peak shedding, often coinciding with the largest cumulative weight loss and the highest dose. Months 6–9: shedding tapers as weight loss slows toward maintenance and follicles re-enter the growth phase. Months 9–12: visible density returns; hair grows roughly half an inch per month, so meaningful regrowth takes that long mechanically. Two practical implications: first, hair loss that starts at month 3 wasn’t triggered last week — it was triggered weeks ago, which is why stopping your medication immediately doesn’t stop the shed. Second, a slower titration with a microdose protocol can flatten the weight-loss curve enough that many patients never trigger telogen effluvium in the first place — the rationale behind the Microdose GLP-1 Protocol at $129/month flat, which uses a lower starting dose across capsule, troche, lozenge, or sublingual delivery and lets the clinician titrate slowly.

Why women report GLP-1 hair loss more often (and the genetic angle most providers miss)

The Zepbound label specifically notes higher hair-loss reporting among women, and real-world reports skew the same way. Several drivers stack on top of each other: women on average enter weight-loss treatment with lower iron stores (ferritin) than men, which matters because ferritin is one of the most consistently identified contributors to telogen effluvium severity; postpartum, perimenopausal, and hypothyroid hair patterns create an underlying vulnerability that rapid weight loss then unmasks; and women are simply more likely to notice and report shedding earlier. The genetic angle is where personalization stops being a buzzword. Variants in GLP1R (the GLP-1 receptor itself), GIPR (the GIP receptor relevant to tirzepatide), FTO (appetite regulation), MC4R (satiety signaling), and TCF7L2 (insulin response) influence both how much weight you lose and how fast — the two factors that drive telogen effluvium risk. The Precision Peptide Genetic Test maps 48 unique genes and 57 variants across 14 health pathways, including 34 weight-management insights and the headline GIPR rs1800437 variant linked to differential GLP-1 response. The test is $298 standalone or $99 as an add-on after your first month on any PlexusDx protocol — a baseline that tells the clinician whether a faster or slower titration is more likely to fit your biology before week one of dosing.

Should you stop your GLP-1 if you’re shedding? (Almost always, no.)

Stopping the medication doesn’t stop the shed — the trigger fired weeks earlier and the follicles in your sink today were committed to telogen back in month two or three. Abrupt discontinuation also tends to produce weight regain, and regain followed by re-initiation can trigger a second round of telogen effluvium on top of the first. The clinical move most experienced GLP-1 providers make is dose adjustment, not discontinuation: hold the current dose, slow further titration, and pull baseline labs. If weight loss has been steeper than 1–2% of body weight per week, slowing the rate is the single biggest lever you have.

The labs, nutrition, and protocol fixes that actually move the needle

The highest-yield workup is unglamorous and inexpensive. Ask your clinician for ferritin (target above 40 ng/mL, not just “within range”), vitamin D, zinc, B12, a thyroid panel with TSH and free T4, and a CBC. Ferritin is the most commonly identified deficiency in GLP-1 hair-loss workups and the easiest to correct. On nutrition, the single most impactful intervention is protein: 70–100 g/day or about 1.0–1.2 g/kg of body weight, prioritized at breakfast since GLP-1 appetite suppression often peaks midday and evenings. Topical minoxidil 2% or 5% is clinically validated for stimulating regrowth and can be used alongside any GLP-1 — results take 3–6 months. Rosemary oil has small-study support as a low-risk complement, not a substitute for fixing nutrition. PlexusDx Weight Management Protocols are cash-pay, no-membership, all-50-states (5 require a live consult), and clinician-managed: Microdose GLP-1 Protocol at $129/mo flat is the lower-and-slower entry that minimizes how fast weight changes in months 1–6; Semaglutide Injection at $149/mo, Tirzepatide Injection at $249/mo, Semaglutide Oral from $249/mo, Tirzepatide Oral at $279/mo, and GLP-Squared at $249/mo each offer multi-step dose ladders so the clinician can hold or step back rather than push through when shedding starts. For patients whose nutrition intent overlaps with broader optimization, the Optimal Diet & Weight Loss Genetic Test ($298) adds 295+ insights on protein response, macronutrient sensitivity, and metabolism.

Frequently asked questions

Does GLP-1 cause hair loss?

Hair loss is a recognized side effect in the FDA labels for Wegovy (about 3% of adults in trials) and Zepbound (4–5% across doses). The strongest evidence points to rapid weight loss as the primary trigger via telogen effluvium, not a direct molecular effect of GLP-1 itself.

Is GLP-1 hair loss permanent?

In the great majority of cases, no. Telogen effluvium is a reversible, non-scarring shedding pattern that resolves within 6–12 months once weight stabilizes and any nutritional deficiencies are corrected. Patterned thinning that persists past 12 months warrants a dermatology evaluation.

When does GLP-1 hair loss start and peak?

Most patients first notice increased shedding 2–4 months after starting treatment or after a dose increase. Peak shedding typically falls between months 4–6, then tapers, with visible regrowth becoming obvious by months 9–12.

Should I stop my GLP-1 because of hair loss?

Almost never as a first move. The shedding you see today was triggered weeks ago, so stopping the medication will not stop the shed and may cause weight regain that triggers a second episode. The right conversation with your clinician is dose adjustment, slower titration, and nutrition correction.

What labs should I ask for?

Ferritin (target above 40 ng/mL), vitamin D, zinc, B12, a thyroid panel with TSH and free T4, and a CBC. Ferritin is the most commonly identified deficiency in GLP-1 hair-loss workups and one of the easiest to correct.

Does a genetic test help with GLP-1 hair loss specifically?

Indirectly but meaningfully. The PlexusDx Precision Peptide Genetic Test ($298 standalone or $99 as an add-on after month one) maps GLP1R, GIPR, FTO, MC4R, and TCF7L2 variants that influence the speed and magnitude of weight loss — the two variables that drive telogen effluvium risk. A slower titration matched to your biology lowers the chance of triggering shedding in the first place.

Will switching from one GLP-1 to another stop the hair loss?

Probably not, since the trigger is rapid weight loss rather than the specific molecule. Switching to a slower-acting protocol like the PlexusDx Microdose GLP-1 Protocol ($129/mo flat) may reduce future risk by flattening the weight-loss curve, but it will not stop a shed that is already in progress.

Related reading on PlexusDx

Related reading on PlexusDx: GLP-1 Side Effects, Wegovy Side Effects, Zepbound Side Effects, GLP-1 Nausea.

Disclaimer: This article is educational and is not medical advice. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols. Pricing and label data for Wegovy, Zepbound, Ozempic, Mounjaro, and Saxenda is based on each manufacturer’s published information as of April 2026; actual experience may vary by state, plan, and individual eligibility. PlexusDx does not sell, prescribe, or recommend any therapeutic peptide outside the GLP-1 category covered by its protocols. Discuss any GLP-1 medication decision — including hair-loss management — with a licensed clinician.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.